The advent of long-acting basal insulin weekly formulations represents a landmark milestone. While ensuring hypoglycemic efficacy and safety, it significantly reduces the injection burden, providing more treatment options for patients with type 2 diabetes (T2DM).At present, icodec insulin, the world’s first insulin weekly formulation, has been included in China’s medical insurance catalogue, and an increasing […]